• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Report: Boston Scientific cut 160 jobs in Minnesota cardiology unit

Report: Boston Scientific cut 160 jobs in Minnesota cardiology unit

June 27, 2011 By MassDevice staff

BSX

Boston Scientific Corp. (NYSE:BSX) cut about 160 workers in its Arden Hill, Minn., facility, according to a press report.

The facility makes pacemakers and implantable cardiac defibrillators, which run through the company’s Cardiac Rhythm Management business unit. News of the cuts were reported by the Pioneer Press newspaper, which based its report on a notice from the the Minnesota Department of Employment and Economic Development.

Rumors of job cuts at BSX’s Arden Hills facility have been rampant since February, when chief medical officer Keith Dawkins told Boston Scientific employees that the job cuts were necessary for the firm to remain competitive, according to a report from Reuters News Service.

In April, press reports again surfaced reporting that the company was issuing pink slips to employees in Arden Hills and that the Natick, Mass.-based medical device giant could cut some 10 percent of its 5,000 employee work force in Minnesota. Nuveen Asset Management analyst Tim Nelson told the Pioneer Press at the time that cuts could run up to 500 jobs.

Boston Scientific has been on an austerity kick for the past two years since J. Raymond Elliott took over as CEO for James Tobin in the summer of 2009. The company announced in early 2010 that it would be cutting 1,300 jobs as part of a global restructuring plan, to “further rationalize and refocus its business portfolio.”

Cuts in the company’s CRM division would not be surprising, as the entire industry is experiencing a slowdown in the number of procedures involving pacemakers and implantable cardiac defibrillators, due to a double whammy of a U.S. Dept. of Justice inquiry and a January JAMA study that said 22.5 percent of patients in the U.S. fell short of medical guidelines to receive an implantable defibrillator.

The report has had a bit of a chilling effect on procedural volumes and was the primary reason BSX took a nearly $700 million impairment of goodwill charge during the first quarter.

“We believe physician reaction to JAMA study results in early January and the DOJ and local inquiries into ICD implant appropriateness of use is contributing, but we don’t believe they will be long-lasting,” CEO Ray Elliott told analysts on an earnings call. “We have taken the U.S. CRM goodwill write-down predominantly as a result of our future view of the market in its entirety, including all the various players.”

Filed Under: News Well Tagged With: Boston Scientific, Personnel Moves

More recent news

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy